1. Home
  2. Press release
Oct 05, 2022 19:55 JST

Source: AIM Vaccine Co., Ltd.

AIM Vaccine Announces Global Offering Results, Offer Price of HK$16.16 per H Share
To Commence Trading on the Main Board of the Hong Kong Stock Exchange on 6 October 2022

HONG KONG, Oct 05, 2022 - (ACN Newswire) - AIM Vaccine Co., Ltd. ("AIM Vaccine" or the "Company", together with its subsidiaries, the "Group", stock code: 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), today announced the allotment results of its Global Offering. The Offer Price is HK$16.16 per H share. Dealings in the H shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange") are expected to commence on 6 October 2022 (Thursday) in board lot of 200 H shares each.

The H shares initially offered under the International Offering were over-subscribed. The net proceeds from the Global Offering are intended for advancing R&D of vaccine candidates and continuing to enrich vaccine pipeline, funding the capital expenditure on the construction of new production facilities for new vaccine products, and investing in sales and marketing activities. The Company said, through one decade of organic growth and external resource integration, AIM Vaccine has become a major player in the Chinese vaccine industry. The official listing on the Hong Kong Stock Exchange marks an important milestone in the history of the development of AIM Vaccine, opening a new chapter for the Company's development. The successful listing shows the trust and support of global investors for the Company's business development, and lays a firm ground for the Company's long-term growth. Looking forward, AIM Vaccine will carry on accelerating the R&D and commercialization process of the pipeline of vaccine candidates, and become a world-class vaccine company, thereby continuing to create greater value for shareholders.


Source: AIM Vaccine Co., Ltd.
Sectors: BioTech, Healthcare & Pharm

Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Latest Release


TOPVISION Launches Prospectus for Listing Transfer from LEAP to the ACE Market
Nov 27, 2024 05:53 JST

TOYOTA GAZOO Racing FULLY PREPARED FOR DAKAR 2025
Nov 26, 2024 17:55 JST

Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
Nov 26, 2024 15:50 JST

Fujitsu develops Policy Twin, a new digital twin technology to maximize effectiveness of local government policies for solving societal issues
Nov 26, 2024 10:51 JST

TOYOTA GAZOO Racing reinforces WRC line-up with youth and experience for 2025
Nov 25, 2024 17:10 JST

Toyota Submits Progress Report on Recurrence Prevention Measures
Nov 25, 2024 15:43 JST

TOPVISION Launches Prospectus for Transfer Listing from LEAP to the ACE Market
Nov 25, 2024 15:00 JST

MHI Thermal Systems Receives Order from Aisan Industry for Aquifer Thermal Energy Storage System for Its New Anjo Plant
Nov 25, 2024 14:18 JST

Oracle Red Bull Racing Driver Max Verstappen Wins Fourth Consecutive F1 Drivers' World Championship
Nov 25, 2024 11:55 JST

Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Nov 22, 2024 11:00 JST

NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth
Nov 21, 2024 22:59 JST

Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan
Nov 21, 2024 15:35 JST

Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Nov 21, 2024 09:00 JST

ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study
Nov 20, 2024 23:05 JST

Start of Demonstration Test of Two-Phase Direct-to-Chip Cooling in the Air-Cooled Data Center
Nov 20, 2024 15:30 JST

Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 11:51 JST

Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 20, 2024 10:24 JST

Kingsoft Announces 2024 Third Quarter Results
Nov 19, 2024 18:54 JST

NTT and Olympus Joint Demonstration Shows IOWN APN's Low-latency Capability Can Be Used for Real-time Diagnosis and Treatment on a Remote Server to Realize World's First Cloud Endoscopy System
Nov 19, 2024 15:30 JST

Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings
Nov 19, 2024 09:02 JST
 More Latest Release >>

Related Release

AIM Vaccine, a Major Player in the Chinese Vaccine Industry, Successfully Listed on the Main Board of SEHK
October 06 2022 19:16 JST
 
AIM Vaccine Announces Proposed Listing on the Main Board of SEHK
September 23 2022 17:06 JST
 
Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance
January 12 2022 10:26 JST
 
More Press release >>